Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.
about
Discovering novel pharmacogenomic biomarkers by imputing drug response in cancer patients from large genomics studies.Adhesion- and stress-related adaptation of glioma radiochemoresistance is circumvented by β1 integrin/JNK co-targeting.Institutional Profile: Pharmacogenomic research in R Stephanie Huang Laboratory.
P2860
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.
@ast
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.
@en
type
label
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.
@ast
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.
@en
prefLabel
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.
@ast
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics.
@en
P2093
P2860
P356
P1476
Predicting Response to Histone Deacetylase Inhibitors Using High-Throughput Genomics
@en
P2093
Andrey Loboda
Bonnie LaCroix
Divya Lenkala
Jacqueline Wang
James Hardwick
Michael Chisamore
Michael L Maitland
Michael Nebozhyn
Paul Geeleher
P2860
P356
10.1093/JNCI/DJV247
P407
P577
2015-08-21T00:00:00Z